CALCOCO1 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 10 of 10 results for "CALCOCO1"
i
  1. CAO1B_XENLA UniProt:Swiss-Prot

    ID: Q6DD09

    Description: Calcium-binding and coiled-coil domain-containing protein 1-B

    gene.name: calcoco1-b
  2. CACO1_BOVIN UniProt:Swiss-Prot

    ID: Q2KJ21

    Description: Calcium-binding and coiled-coil domain-containing protein 1 N-terminal AD (CTNNB1 binding site) p300 KIX-binding Interaction with GATA1 C-terminal AD ...

    gene.name: CALCOCO1
  3. Breast tumors from CHEK2 1100delC mutation carriers: genomic landscape and clinical implications (GEX) ArrayExpress

    ID: E-GEOD-24697

    Description: drivers. These included CLCA1 on 1p22 as well as CALCOCO1, SBEM and LRP1 on 12q13. Altogether 188 genes were differentially expressed between CHEK2 1100delC and other tumors. Of these, 144 had elevated and 44 lowered expression levels. Our results suggest WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC mutation carriers and a role for the olfactory receptor protein family in cancer progression. Differences in the expression of the 188 CHEK2 1100delC associated genes divided breast tumor samples from three independent datasets into two groups that differed in their relapse-free survival time. Conclusions: We have shown that copy number aberrations of certain genomic regions are associated with CHEK2 mutation 1100delC. On these regions we have identified potential drivers of CHEK2 1100delC associated tumorigenesis, whose role in cancer progression is worth investigating. Furthermore, poorer survival related to the CHEK2 1100delC gene expression signature highlights pathways that are likely to have a role in the development of metastatic disease in carriers of CHEK2 1100delC mutation. 78 samples from breast tumors: 13 tumors from CHEK2 1100delC mutation carriers, 65 other tumors...

  4. Breast tumors from CHEK2 1100delC mutation carriers: genomic landscape and clinical implications (CGH) ArrayExpress

    ID: E-GEOD-24698

    Description: drivers. These included CLCA1 on 1p22 as well as CALCOCO1, SBEM and LRP1 on 12q13. Altogether 188 genes were differentially expressed between CHEK2 1100delC and other tumors. Of these, 144 had elevated and 44 lowered expression levels. Our results suggest WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC mutation carriers and a role for the olfactory receptor protein family in cancer progression. Differences in the expression of the 188 CHEK2 1100delC associated genes divided breast tumor samples from three independent datasets into two groups that differed in their relapse-free survival time. Conclusions: We have shown that copy number aberrations of certain genomic regions are associated with CHEK2 mutation 1100delC. On these regions we have identified potential drivers of CHEK2 1100delC associated tumorigenesis, whose role in cancer progression is worth investigating. Furthermore, poorer survival related to the CHEK2 1100delC gene expression signature highlights pathways that are likely to have a role in the development of metastatic disease in carriers of CHEK2 1100delC mutation. 79 samples from breast tumors: 22 tumors from CHEK2 1100delC mutation carriers, 57 other tumors Five files attached represent segmented values, copy number calls, gain, loss and normal copy number probabilities....

  5. GATA1_RAT UniProt:Swiss-Prot

    ID: P43429

    Description: uired for interaction with ZFPM1 Interaction with CALCOCO1 Phosphoserine Phosphoserine Phosphoserine Phosphoserine Phosphoserine Phosphoserine N6-acetyllysine; by EP300 N6-acetyllysine; by EP300 N6-acetyllysine; by CREBBP N6-acetyllysine; by EP300 N6-acetyllysine; by CRE...

  6. (Dex)-regulated, CARP1/CCAR1-, DBC1/CCAR2, CoCoA/CALCOCO1- or HUB1/ZNF282-dependent transcriptomes in A549 lung cancer cells.... NURSA

    Keywords: epithelium A549 cells

    Description: ith control (NC), CARP1/CCAR1-, DBC1/CCAR2, CoCoA/CALCOCO1- or HUB1/ZNF282 siRNAs and treated with or without 100 nM Dex for 6 h....

    ID: 10.1621/0Lc5z4wSdO

  7. Breast tumors from CHEK2 1100delC mutation carriers: genomic landscape and clinical implications (GEX) BioProject

    ID: PRJNA133633

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: drivers. These included CLCA1 on 1p22 as well as CALCOCO1, SBEM and LRP1 on 12q13. Altogether 188 genes were differentially expressed between CHEK2 1100delC and other tumors. Of these, 144 had elevated and 44 lowered expression levels. Our results suggest WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC mutation carriers and a role for the olfactory receptor protein family in cancer progression. Differences in the expression of the 188 CHEK2 1100delC associated genes divided breast tumor samples from three independent datasets into two groups that differed in their relapse-free survival time. Conclusions: We have shown that copy number aberrations of certain genomic regions are associated with CHEK2 mutation 1100delC. On these regions we have identified potential drivers of CHEK2 1100delC associated tumorigenesis, whose role in cancer progression is worth investigating. Furthermore, poorer survival related to the CHEK2 1100delC gene expression signature highlights pathways that are likely to have a role in the development of metastatic disease in carriers of CHEK2 1100delC mutation. Overall design: 78 samples from breast tumors: 13 tumors from CHEK2 1100delC mutation carriers, 65 other tumors...
  8. Breast tumors from CHEK2 1100delC mutation carriers: genomic landscape and clinical implications (CGH) BioProject

    ID: PRJNA133635

    Keywords: Variation

    Access Type: download

    dataset.description: drivers. These included CLCA1 on 1p22 as well as CALCOCO1, SBEM and LRP1 on 12q13. Altogether 188 genes were differentially expressed between CHEK2 1100delC and other tumors. Of these, 144 had elevated and 44 lowered expression levels. Our results suggest WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC mutation carriers and a role for the olfactory receptor protein family in cancer progression. Differences in the expression of the 188 CHEK2 1100delC associated genes divided breast tumor samples from three independent datasets into two groups that differed in their relapse-free survival time. Conclusions: We have shown that copy number aberrations of certain genomic regions are associated with CHEK2 mutation 1100delC. On these regions we have identified potential drivers of CHEK2 1100delC associated tumorigenesis, whose role in cancer progression is worth investigating. Furthermore, poorer survival related to the CHEK2 1100delC gene expression signature highlights pathways that are likely to have a role in the development of metastatic disease in carriers of CHEK2 1100delC mutation. Overall design: 79 samples from breast tumors: 22 tumors from CHEK2 1100delC mutation carriers, 57 other tumors Five files attached represent segmented values, copy number calls, gain, loss and normal copy number probabilities....
  9. Breast tumors from CHEK2 1100delC mutation carriers: genomic landscape and clinical implications (GEX) OmicsDI

    ID: E-GEOD-24697

    Date Released: 05-02-2014

    Description: drivers. These included CLCA1 on 1p22 as well as CALCOCO1, SBEM and LRP1 on 12q13. Altogether 188 genes were differentially expressed between CHEK2 1100delC and other tumors. Of these, 144 had elevated and 44 lowered expression levels. Our results suggest WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC mutation carriers and a role for the olfactory receptor protein family in cancer progression. Differences in the expression of the 188 CHEK2 1100delC associated genes divided breast tumor samples from three independent datasets into two groups that differed in their relapse-free survival time. Conclusions: We have shown that copy number aberrations of certain genomic regions are associated with CHEK2 mutation 1100delC. On these regions we have identified potential drivers of CHEK2 1100delC associated tumorigenesis, whose role in cancer progression is worth investigating. Furthermore, poorer survival related to the CHEK2 1100delC gene expression signature highlights pathways that are likely to have a role in the development of metastatic disease in carriers of CHEK2 1100delC mutation. 78 samples from breast tumors: 13 tumors from CHEK2 1100delC mutation carriers, 65 other tumors...

  10. Breast tumors from CHEK2 1100delC mutation carriers: genomic landscape and clinical implications (CGH) OmicsDI

    ID: E-GEOD-24698

    Date Released: 05-02-2014

    Description: drivers. These included CLCA1 on 1p22 as well as CALCOCO1, SBEM and LRP1 on 12q13. Altogether 188 genes were differentially expressed between CHEK2 1100delC and other tumors. Of these, 144 had elevated and 44 lowered expression levels. Our results suggest WNT pathway as a driver of tumorigenesis in breast tumors of CHEK2 1100delC mutation carriers and a role for the olfactory receptor protein family in cancer progression. Differences in the expression of the 188 CHEK2 1100delC associated genes divided breast tumor samples from three independent datasets into two groups that differed in their relapse-free survival time. Conclusions: We have shown that copy number aberrations of certain genomic regions are associated with CHEK2 mutation 1100delC. On these regions we have identified potential drivers of CHEK2 1100delC associated tumorigenesis, whose role in cancer progression is worth investigating. Furthermore, poorer survival related to the CHEK2 1100delC gene expression signature highlights pathways that are likely to have a role in the development of metastatic disease in carriers of CHEK2 1100delC mutation. 79 samples from breast tumors: 22 tumors from CHEK2 1100delC mutation carriers, 57 other tumors Five files attached represent segmented values, copy number calls, gain, loss and normal copy number probabilities....


Displaying 10 of 10 results for "CALCOCO1"